Great Lakes NeuroTechnologies announced today that they are launching the latest version of their medical device technology for assessing Parkinson’s disease next week at the Movement Disorders Society Congress in Dublin, Ireland.
The Kinesia HomeView™ system includes patient-worn motion sensors and a tablet computer to quantitatively assess tremor, bradykinesia, and dyskinesia associated with Parkinson’s disease and in response to treatments. Physicians utilize a web interface to setup patient studies and track symptom responses over the course of the day. Market applications include both in-clinic and home-based telemedicine patient care, programming deep brain stimulation, and providing quantitative endpoints to determine efficacy of clinical trials.
The latest system infrastructure includes several key technology updates to improve the telemedicine experience for Parkinson’s patients, physicians, and researchers. First, the patient take-home kit supports broadband data transfer directly from a patient’s home to a secure server. This allows physicians and researchers immediate online access to real-time symptom reports and video diaries.
Next, miniature, patient-worn motion sensors are instrumented with wireless communications. This minimizes setup time and patient burden during home-based assessments.
Finally, physicians and researchers can use their own tablets to view web-based reports. Color-coded mapping provides intuitive, quantitative tools to document symptom severity and motor fluctuations.
“As broadband and wireless technologies have matured along with the tablet PC market, our development team has been able to successfully integrate them into the Kinesia platform”, said Greg Ferreri, Software Engineering Manager. “By listening to our customers’ requirements, we have used the latest development tools to improve the patient and physician experience for telemedicine and clinical trials.”
For the last decade, Great Lakes NeuroTechnologies has been the worldwide leader in developing quantitative, home-based assessment tools for Parkinson’s disease. Fueled by strong funding support from the National Institutes of Health in the United States, including the National Institute of Neurological Disorders and Stroke and the National Institute on Aging, Kinesia HomeView has been commercialized and clinically validated in numerous studies and hundreds of patients.
“Great Lakes NeuroTechnologies is now uniquely positioned in the movement disorders market as a global leader in medical device manufacture and commercialization of technologies to standardize, automate, and remotely capture movement disorder patient assessments.” says Joseph P. Giuffrida, PhD, President.
“We are excited to continue meeting the needs of our growing customer base in quantitative movement disorders assessment. The launch of our system in Europe highlights our commitment to expanded international marketing and sales, building upon our foundation of strong science and technology development, FDA clearance, ISO certification, CE mark, and broad claims for intellectual property protection.”
About Great Lakes NeuroTechnologies
Great Lakes NeuroTechnologies is committed to pioneering innovative biomedical technologies to serve research, education, and medical communities, improving access to medical technology for diverse populations, and positively impacting quality of life for people around the world.
Novel SARS-CoV-2 mutations found in floodwaters near homeless communities